Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wilfried Obst

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
HIV Research & Clinical Practice|March 2, 2022
Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changesMalte Monin, Tim Kümmerle, Jochen Schneider, et al.
Open Forum Infectious Diseases|September 23, 2020
Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS StudyChristoph D Spinner, Tim Kümmerle, Jochen Schneider, et al.
Infection|May 3, 2024
Comparison of post-COVID-19 symptoms in patients infected with the SARS-CoV-2 variants delta and omicron-results of the Cross-Sectoral Platform of the German National Pandemic Cohort Network (NAPKON-SUEP)Sina M Hopff, Katharina S Appel, Olga Miljukov, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
HIV Research & Clinical Practice|March 2, 2022
Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changesMalte Monin, Tim Kümmerle, Jochen Schneider, et al.
Open Forum Infectious Diseases|September 23, 2020
Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS StudyChristoph D Spinner, Tim Kümmerle, Jochen Schneider, et al.
Infection|May 3, 2024
Comparison of post-COVID-19 symptoms in patients infected with the SARS-CoV-2 variants delta and omicron-results of the Cross-Sectoral Platform of the German National Pandemic Cohort Network (NAPKON-SUEP)Sina M Hopff, Katharina S Appel, Olga Miljukov, et al.
Pageof 2